Saphnelo® (Anifrolumab-Fnia) – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers Saphnelo (anifrolumab‑fnia) for adults with moderate‑to‑severe SLE but excludes use in severe active lupus nephritis or severe active CNS lupus and prohibits combination with other biologics (including belimumab/Benlysta). Coverage requires concomitant non‑biologic standard therapy, dosing per FDA label, rheumatology prescriber/consult, authorizations ≤12 months (continuation requires prior IV administration and documented clinical benefit), and for Medicare reviews an initial contraindication/intolerance/failure to Benlysta is required.

" - Saphnelo is dosed according to US Food and Drug Administration labeled dosing for SLE; and"

Sign up to see full coverage criteria, indications, and limitations.